치료 역사

흑색종 치료 발전 타임라인

발견과 승인은 치료 선택의 역사를 보여줍니다. 하지만 개인에게 맞는 치료, 자격, 순서를 결정하지 않습니다.

1. local therapy

   pre-2000s: Surgery and pathology remain the foundation for localized melanoma

   Removing melanoma and reading the pathology report remain central for early-stage and selected local situations.

   무엇이 바뀌었나

   Modern systemic options did not remove the need for careful staging, margins, lymph-node questions, and pathology review.

   추정하면 안 되는 것

   Surgery alone does not answer whether surveillance, adjuvant therapy, radiation, systemic therapy, or trial discussion is needed.

   clinical-trials

   의학적 세부 내용의 출처

   1. Melanoma Treatment (PDQ) - Patient Version. 확인일 2026-05-20.
   2. Melanoma Treatment (PDQ) - Health Professional Version. 확인일 2026-05-20.
2. immunotherapy

   2011: Ipilimumab opens the checkpoint inhibitor era in melanoma

   A CTLA-4 checkpoint inhibitor became an approved melanoma immunotherapy option.

   무엇이 바뀌었나

   Melanoma treatment shifted from mostly chemotherapy/local approaches toward immune checkpoint strategies.

   추정하면 안 되는 것

   Checkpoint therapy can have serious immune side effects and does not fit every patient or every sequence.

   ipilimumabnivolumab-ipilimumab

   의학적 세부 내용의 출처

   1. FDA approval context for ipilimumab in unresectable or metastatic melanoma. 확인일 2026-05-21.
   2. Drugs Approved for Melanoma. 확인일 2026-05-20.
3. targeted therapy

   2011: BRAF-targeted therapy arrives with vemurafenib

   A drug targeting BRAF V600-mutant melanoma showed how mutation testing could change the treatment conversation.

   무엇이 바뀌었나

   Mutation results became more directly tied to treatment categories in melanoma.

   추정하면 안 되는 것

   BRAF drugs are not for NRAS-only melanoma unless the report also documents qualifying BRAF mutation.

   melanoma-braf-v600braf-mek-combinationsvemurafenib-cobimetinib

   의학적 세부 내용의 출처

   1. NCI: Vemurafenib. 확인일 2026-05-21.
   2. Melanoma Treatment (PDQ) - Health Professional Version. 확인일 2026-05-20.
4. immunotherapy

   2014-2015: PD-1 inhibitors and checkpoint combinations expand

   Pembrolizumab and nivolumab became major PD-1 checkpoint inhibitor names, and nivolumab plus ipilimumab expanded the combination conversation.

   무엇이 바뀌었나

   Families increasingly heard PD-1, CTLA-4, response duration, immune toxicity, and sequencing language.

   추정하면 안 되는 것

   PD-1 drugs are not MEK inhibitors, and a prior PD-1 failure changes later trial and treatment questions.

   nivolumab-pembrolizumab-pd1nivolumabpembrolizumabnivolumab-ipilimumab

   의학적 세부 내용의 출처

   1. NCI: Pembrolizumab for Advanced Melanoma. 확인일 2026-05-21.
   2. NCI: FDA expands nivolumab uses, including nivolumab plus ipilimumab in melanoma. 확인일 2026-05-21.
   3. Melanoma Treatment (PDQ) - Patient Version. 확인일 2026-05-20.
5. local therapy

   2015: T-VEC adds an injectable/local immunotherapy lane

   An intralesional therapy became part of selected melanoma local-treatment discussions.

   무엇이 바뀌었나

   Local therapy could include more than surgery or radiation in selected lesion-specific situations.

   추정하면 안 되는 것

   Injectable local therapy is not the same as a whole-body systemic treatment.

   t-vec

   의학적 세부 내용의 출처

   1. Drugs Approved for Melanoma. 확인일 2026-05-20.
   2. Melanoma Treatment (PDQ) - Patient Version. 확인일 2026-05-20.
6. immunotherapy

   2022: Nivolumab plus relatlimab adds PD-1 + LAG-3 language

   A checkpoint combination using PD-1 and LAG-3 became part of U.S. melanoma source context.

   무엇이 바뀌었나

   Families may now hear LAG-3 alongside PD-1 and CTLA-4.

   추정하면 안 되는 것

   It does not automatically replace PD-1 alone, nivolumab plus ipilimumab, targeted therapy, TIL, or trials.

   nivolumab-relatlimab

   의학적 세부 내용의 출처

   1. FDA approval of Opdualag (nivolumab and relatlimab-rmbw) for unresectable or metastatic melanoma. 확인일 2026-05-20.
   2. Drugs Approved for Melanoma. 확인일 2026-05-20.
7. cell therapy

   2024: Lifileucel / TIL therapy receives accelerated approval

   A tumor-infiltrating lymphocyte therapy became a U.S. approved melanoma option in a specific post-treatment context.

   무엇이 바뀌었나

   Cell therapy became part of the melanoma options vocabulary outside trials for selected adults.

   추정하면 안 되는 것

   TIL therapy is not broadly available everywhere and has specific prior-treatment, center, and patient-fitness requirements.

   lifileucel-til

   의학적 세부 내용의 출처

   1. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. 확인일 2026-05-20.
   2. Drugs Approved for Melanoma. 확인일 2026-05-20.
8. targeted therapy

   2024: China conditionally approves tunlametinib for NRAS-mutant advanced melanoma context

   A China-specific MEK inhibitor became especially important for MatchMedi because of the NRAS melanoma lived context.

   무엇이 바뀌었나

   NRAS melanoma families may encounter country-specific options that do not map cleanly to U.S. availability.

   추정하면 안 되는 것

   Tunlametinib should not be assumed available outside China, and tunlametinib plus nivolumab remains unresolved as exact melanoma evidence.

   tunlametinib-hl-085tunlametinib-nivolumab-unresolved

   의학적 세부 내용의 출처

   1. Tunlametinib Capsules approved with conditions for marketing by China NMPA. 확인일 2026-05-20.
   2. NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma. 확인일 2026-05-20.